How film making is providing better treatments with existing drugs




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: How film making is providing better treatments with existing drugs
Released on: November 13, 2014. © PTV
Visitors: You are watching a 1 minute preview.
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    AcuCort’s Bengt Westrin describes how a virtual Swedish Biotech has re-engineered the delivery of one of the most widely used steroids to better address unmet needs in allergy and cancer supportive care.
  • Summary
  • Transcript
  • Participants
  • Company
AcuCort’s Bengt Westrin describes how a virtual Swedish Biotech has re-engineered the delivery of one of the most widely used steroids to better address unmet needs in allergy and cancer supportive care.
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Bengt Westrin
AcuCort
Today, there is no convenient and user-friendly glucocorticoid product for the acute allergic situation. The current golden standard is to give antihistamines and glucocorticoids and – if the reaction is severe – an adrenalin injection. However, for someone suffering an anaphylactic reaction, or for a child in a very upset condition, conventional glucocorticoid tablets can be problematic to swallow, in particular if a large number of low strength tablets are needed or if no water is available. Cancer patients in chemotherapy treatment and suffering from nausea, vomiting or impaired ability to swallow is another patient group for which the conventional tablet is not the optimal dosage form. There is thus a gap in the treatment arsenal, a gap that can be filled by a product with the same effect but with another administration form. AcuCort is filling that gap. AcuCort’s rapidly dissolving product is easily put on the tongue and the patient will achieve the same effect as with the 4-16 conventional tablets usually needed to achieve the desired dose. AcuCort’s product can also be administered by a parent or someone else without medical training helping the patient.
AcuCort
Today, there is no convenient and user-friendly glucocorticoid product for the acute allergic situation. The current golden standard is to give antihistamines and glucocorticoids and – if the reaction is severe – an adrenalin injection. However, for someone suffering an anaphylactic reaction, or for a child in a very upset condition, conventional glucocorticoid tablets can be problematic to swallow, in particular if a large number of low strength tablets are needed or if no water is available. Cancer patients in chemotherapy treatment and suffering from nausea, vomiting or impaired ability to swallow is another patient group for which the conventional tablet is not the optimal dosage form. There is thus a gap in the treatment arsenal, a gap that can be filled by a product with the same effect but with another administration form. AcuCort is filling that gap. AcuCort’s rapidly dissolving product is easily put on the tongue and the patient will achieve the same effect as with the 4-16 conventional tablets usually needed to achieve the desired dose. AcuCort’s product can also be administered by a parent or someone else without medical training helping the patient.